New Day Diagnostics launches new test for axial spondyloarthritis
AxSpA, as its is known, is a debilitating form of inflammatory arthritis that targets the spine and sacroiliac joints, frequently causing chronic pain, spinal damage, and mobility issues.
Augurex Life Sciences Corp., located in Vancouver, British Columbia, has announced the launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test that assists clinicians in the diagnosis of axial spondyloarthritis (axSpA).
And, guess who developed the test? It was Knoxville-based New Day Diagnostics using the Anti-14-3-3eta Multiplex ASRs as components and now offers the test through physician order only. The novel diagnostic test is designed to empower clinicians to identify axSpA at an earlier stage, potentially addressing the often-lengthy diagnostic delay and improving outcomes for patients.
AxSpA is a debilitating form of inflammatory arthritis that targets the spine and sacroiliac joints, frequently causing chronic pain, spinal damage, and mobility issues. Despite its profound impact, axSpA patients have faced an average diagnostic delay of 7 to 10 years. This extensive delay is due in part to the absence of reliable biomarkers detectable through diagnostic testing techniques, often relying on costly imaging procedures that aren’t accessible to all.
Early diagnosis is essential as it enables timely intervention that can slow disease progression, preserve mobility, and significantly improve patient outcomes. Anti-14-3-3eta Multiplex ASRs help clinical laboratories detect Anti-14-3-3eta autoantibodies; biomarkers indicative of certain autoimmune disorders such as axSpA. Diagnostic tests for axSpA using the Anti-14-3-3eta Multiplex ASRs aim to address the critical need of axSpA patients by equipping clinicians with essential tools to aid in the early diagnosis of axSpA, enabling timely treatment.
“The availability of the Anti-14-3-3eta Multiplex ASRs for axSpA marks a significant advancement in diagnostics and has enabled the development of novel laboratory developed tests,” said Eric Mayer, President and Chief Executive Officer of New Day Diagnostics. “Our test, which uses Augurex’s ASRs as components, provides clinicians with an accessible and reliable tool for identifying a condition that is often missed, helping patients receive targeted care earlier.”
Like what you've read?
Forward to a friend!